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Long noncoding RNAs (lncRNAs) are functional molecules that orchestrate gene expression. To identify lncRNAs
involved in nonalcoholic fatty liver disease (NAFLD) severity, we performed a multiscale study that included: (a) sys-
tems biology modeling that indicated metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) as a candidate
lncRNA for exploring disease-related associations, (b) translational exploration in the clinical setting, and (c) mechanis-
tic modeling. MALAT1 liver profiling was performed in three consecutive phases, including an exploratory stage (liver
samples from patients with NAFLD who were morbidly obese [n 5 47] and from 13 individuals with normal liver his-
tology); a replication stage (patients with NAFLD and metabolic syndrome [n 549]); and a hypothesis-driven stage
(patients with chronic hepatitis C and autoimmune liver diseases, [n 5 65]). Liver abundance of MALAT1 was associ-
ated with NAFLD severity (P 5 1 3 10–6); MALAT1 expression levels were up-regulated 1.75-fold (P 5 0.029) and
3.6-fold (P 5 0.012) in patients with nonalcoholic steatohepatitis compared to those diagnosed with simple steatosis
(discovery and replication set, respectively; analysis of covariance adjusted by age, homeostasis model assessment, and
body mass index). Quantification of liver vascular endothelial growth factor A messenger RNA, a target of MALAT1,
revealed a significant correlation between the two RNAs (R, 0.58; P 5 5 3 10–8). Increased levels of MALAT1 were
also associated with autoimmune liver diseases. Interactome assessment uncovered significant biological pathways,
including Janus kinase-signal transducers and activators of transcription and response to interferon-c. Conclusion:
Deregulated expression of MALAT1 stratifies patients into the histologic phenotypes associated with NAFLD severity.
MALAT1 up-regulation seems to be a common molecular mechanism in immune-mediated chronic inflammatory liver
damage. This suggests that convergent pathophenotypes (inflammation and fibrosis) share similar molecular mediators.
(Hepatology Communications 2018;2:654-665)
Nonalcoholic fatty liver disease (NAFLD) isa chronic liver disorder that exhibitscomplex phenotypic diversity.(1) The scope of
the histologic disease severity varies, ranging from a
relatively benign and mild condition known as simple
(bland) steatosis or nonalcoholic fatty liver (NAFL) to
a more severe histologic picture characterized by liver
cell injury, a mixed inflammatory lobular infiltrate, and
variable fibrosis, referred to as nonalcoholic steatohepa-
titis (NASH).(2) These main histologic phenotypes
Abbreviations: BMI, body mass index; GEO, Gene Expression Omnibus; GO, gene ontology; HCC, hepatocellular carcinoma; HCV, hepatitis C
virus; JAK-STAT, Janus kinase-signal transducers and activators of transcription; lncRNA, long noncoding RNA; MALAT1, metastasis-associated
lung adenocarcinoma transcript 1; MetS, metabolic syndrome; mRNA, messenger RNA; NAFL, nonalcoholic fatty liver; NAFLD, nonalcoholic fatty
liver disease; NASH, nonalcoholic steatohepatitis; NRF, nuclear respiratory factor; PCR, polymerase chain reaction; TF, transcription factor; VEGFA,
vascular endothelial growth factor A.
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(NAFL and NASH) display distinctive degrees of
severity.(2)
Irrespective of whether NAFL and NASH should
be considered as having different long-term clinical
impact, it is clear that the progression of NASH into
more aggressive phenotypes, including NASH fibrosis
and NASH cirrhosis and eventually hepatocellular car-
cinoma (HCC), imposes a tremendous public health
problem of epidemic proportions.(1,3)
While the molecular mechanisms that drive the
severity and progression of NAFLD and NASH are
an important subject of a large body of scientific
research, transcriptome analysis of liver tissue has pro-
vided the most compelling information of deregulated
signatures operating at the gene level that modulate
the natural history of the disease.(4,5) Nevertheless,
with the exception of recent reports,(6,7) most findings
yielded by previous studies indicated aberrant patterns
of liver expression of messenger RNAs (mRNAs).
Virtually 60% of the human transcriptome is repre-
sented by long RNAs (with length exceeding 200
nucleotides) that lack protein-coding capacity and are
thus referred to as long noncoding RNAs (lncRNAs).(8)
LncRNAs play a remarkable role not only in regulating
the entire transcriptome by interacting with multiple
mRNAs and modulating epigenetic mechanisms but
also in posttranslational regulation and direct interfer-
ence with protein activity.(9) Ultimately, lncRNAs are
involved in the orchestration of cell-to-cell signaling
and cell functioning.(9) Consequently, it is plausible to
hypothesize that lncRNAs may be involved not only in
NAFLD pathogenesis(10) but also in determining the
fate of the disease course and severity.
Patients and Methods
STUDY DESIGN AND PATIENT
SELECTION CRITERIA
To identify lncRNAs involved in NAFLD severity,
we performed a multidimensional study that included
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the following: a core of multiscale systems biology
modeling in four hierarchical dimensions (data mining
of biological terms, building of a NAFLD interaction
network, and searching and prioritization of lncRNA–
mRNA interactions); translational exploration in the
clinical setting (expression profiling of a candidate
lncRNA in the liver tissue of affected patients); and
mechanistic modeling (analysis of co-expression inter-
actions). A detailed workflow depicting all study stages
is shown in Fig. 1.
This strategy indicated metastasis-associated
lung adenocarcinoma transcript 1 (MALAT1;
alias names LINC00047, NEAT2, NCRNA00047,
ENSG00000251562) as a candidate lncRNA for
exploring disease-related associations. Liver profiling
of MALAT1 expression levels was performed in three
consecutive study phases involving 174 unrelated
patients. Specifically, 47 patients with NAFLD and
morbid obesity (n 5 47) took part in the exploratory
stage; 49 individuals with NAFLD and metabolic
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FIG. 1. Flow chart of work undertaken. Literature mining was performed using the PESCADOR tool, a web resource that allows
exploring interactions between genes and proteins by identifying the co-occurrences of their terms in data extracted from the National
Center for Biotechnology Information’s PubMed database. The NAFLD interaction network was modeled using the resource
VisANT. LncRNA2Target(40) (http://bio-annotation.cn/lncrna2target/) and LncRNA2Function(40) (http://bio-annotation.cn/lncrna2-
target/) were used to explore and prioritize lncRNA2mRNA interactions. LncRNA2Function identifies protein-coding genes that are
significantly co-expressed with one or more lncRNAs across 19 normal human tissues; target genes of an lncRNA are defined as the
differentially expressed genes after knocking down or overexpressing the lncRNA. The function of the candidate lncRNA MALAT1
was explored using the FARNA tool, a knowledge base of inferred functions of 10,289 human noncoding RNA transcripts (compris-
ing 2,734 microRNAs and 7,555 lncRNAs) in 119 human tissues and 177 primary cells. Pathway analysis was performed using the
PANTHER tool; normal MALAT1 cell expression levels were extracted from the BIOPGS gene-expression atlas, while profiling was
performed using Affymetrix tiling arrays (U133 Affymetrix chip).
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syndrome (MetS; n5 49) were involved in the replica-
tion stage; and 65 patients diagnosed with chronic liver
disease of diverse etiology participated in the subse-
quent hypothesis-driven stage, 44 of whom were
therapy-naive subjects with chronic hepatitis C virus
(HCV) infection (n 5 44), while the remaining 21
had autoimmune liver diseases (n 5 21). Details can
be found in the Supporting Material.
All investigations performed as part of the present
study were conducted in accordance with the guide-
lines of the 1975 Declaration of Helsinki. Written
consent from the participating individuals was
obtained in accordance with the procedures approved
by the ethical committee of our institution (protocol
numbers 104/HGAZ/09, 89/100, and 1204/2012).
PHYSICAL, ANTHROPOMETRIC,
AND BIOCHEMICAL
EVALUATION
Details of the physical, anthropometric, and
biochemical evaluations can be found in the Support-
ing Material.
HISTOLOGIC EVALUATION
NAFLD disease severity was assessed by liver biopsy
(performed before any intervention) with ultrasound
guidance and a modified 1.4-mm-diameter Menghini
needle (Hepafix, Braun, Germany) under local anes-
thesia on an outpatient basis or during bariatric surgery
in which surgically excised samples from the left lobe
were immediately collected after the abdomen was
opened and before organs were manipulated.
A portion of each liver biopsy specimen was routinely
fixed in 40 g/L formaldehyde (pH 7.4), embedded in
paraffin, and stained with hematoxylin and eosin,
Masson trichrome, and silver impregnation for reticular
fibers. All biopsies were at least 3 cm in length and con-
tained a minimum of eight portal tracts. Degree of stea-
tosis was assessed according to the system developed by
Kleiner et al.(11) based on the percentage of hepatocytes
containing macrovesicular fat droplets. NASH and
NAFLD activity score were defined as reported(11,12);
NASH was defined as steatosis plus mixed inflamma-
tory cell infiltration, hepatocyte ballooning and necrosis,
Mallory’s hyaline, and any stage of fibrosis, including
absent fibrosis.(11,12) In patients with chronic HCV,
liver histopathology was scored according to Ishak’s
fibrosis grading and staging system.(13)
RNA PREPARATION AND REAL-
TIME REVERSE-TRANSCRIPTION
POLYMERASE CHAIN REACTION
FOR QUANTITATIVE
ASSESSMENT OF lncRNA AND
mRNA EXPRESSION
Total RNA was prepared from liver tissue using the
phenol extraction step method, with an additional
deoxyribonuclease digestion. After extraction, RNA
quantity was measured using the ND-1000 spectropho-
tometer (NanoDrop Technologies, Wilmington, DE).
For reverse-transcription polymerase chain reaction
(PCR), 1-3 lg of total RNA was reverse transcribed
using high capacity complementary DNA reverse tran-
scriptase (Life Technologies, Camarillo, CA).
Real-time PCR was performed for quantitative
assessment of lncRNA and mRNA expression in a
Step One Plus Real-Time PCR System (Applied Bio-
systems, Buenos Aires, Argentina).
MALAT1 RNA liver expression was assessed by a
TaqMan noncoding RNA gene expression assay
(Assay ID, Hs01910177_s1) according to the specifi-
cations of the manufacturer (Life Technologies, Bue-
nos Aires, Argentina). RNA or mRNA abundance of
target genes was normalized to the amount of a house-
keeping gene (ribosomal protein L19 [RPL19]) to
carry out comparisons between groups. The selection
of the housekeeping gene was based on the exploration
of the most stable reference gene for testing liver
mRNA expression among other housekeeping genes
tested before starting this experiment. The geNorm
program(14) was used to identify the appropriate refer-
ence control in our samples. Primer sequences are
shown in Supporting Table S1. All real-time PCR
reactions were run in duplicate. The lncRNA or
mRNA levels were expressed as the ratio of the esti-
mated amount of target gene relative to RPL19
mRNA levels, using fluorescence threshold cycle values
calculated for each sample; the estimated efficiency of
the PCR for each product was expressed as the average
of all sample efficiency values obtained.
STATISTICAL ANALYSIS
Quantitative data were expressed as mean 6 SE
unless otherwise indicated. Because significant differ-
ences in variance were observed between groups for most
variables and the distribution was significantly skewed in
most cases, we chose to be conservative and assessed the
differences between groups by using the nonparametric
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Mann-Whitney U test. As indicated in some compari-
sons, log-transformed variables were compared by
analysis of variance for mean differences. Univariate
correlations were obtained with the Spearman’s rank
correlation test. For logistic analysis or analysis of covari-
ance, we adjusted for co-variables that were not normally
distributed through log-transformation. Significance
was assessed using a nominal P value of 0.05. The CSS/
Statistica program package version 6.0 (StatSoft, Tulsa,
OK) was used in the analyses.
Results
SYSTEMS BIOLOGY MODELING
INDICATED MALAT1 AS A
CANDIDATE lncRNA IN THE
BIOLOGY OF NAFLD
We followed the multistage system biology strategy
(Fig. 1) to identify a significant lncRNA potentially
involved in the biology of NAFLD. Modeling
included several hierarchical levels of biological
abstraction. First, we identified relevant biological
terms by data mining using the terms “LncRNA OR
long non-coding RNA OR RNA” and “fatty liver OR
NAFLD OR FLD” and Medical Subject Heading
terms. In our search, we used the PESCADOR plat-
form for exploration of significant concepts associated
with relationship co-occurrences.
Second, we built the NAFLD interaction network
using the platform visANT, which consisted of different
levels of gene/protein interactions, co-expression pat-
terns, and gene ontology (GO) terms. Hierarchical
exploration revealed metanodes that resulted from
annotation enrichment analysis (Supporting Fig. S1).
Third, we explored the presence of lncRNA2mRNA
interactions using the platform LncRNATarget (http://
bio-annotation.cn/lncrna2target/), which is based on
information of validated targets and/or targets differen-
tially expressed after knockdown or overexpression of
lncRNAs. Prioritization of candidate lncRNAs was
further analyzed with the LncRNA2Function resource
(http://bio-annotation.cn/lncrna2target/), which identi-
fies gene co-expressed patterns among lncRNA–
mRNA pairs along with GO terms and pathway
enrichment based on RNA sequencing data. LncRNAs
known to be expressed in the liver tissue or were pre-
dicted to have interactions with genes/proteins involved
in metabolic pathways were selected.
The NAFLD interaction network yielded a list of
494 genes. Subsequent prioritization of mRNA–
lncRNA interactions revealed 10 candidate lnRNAs
potentially involved in gene expression regulation (Fig.
1). Based on assessment of tissue-specific and co-
expression patterns, we selected the lncRNAMALAT1
for further exploration. MALAT1 is a 8.7-kb gene
located in chromosome 11q13 that is highly conserved
across species.(15) This gene produces a precursor tran-
script from which an lncRNA is derived by ribonucle-
ase P cleavage of a transfer RNA-like small noncoding
RNA (known as MALAT1-associated small cytoplas-
mic RNA) from its 30 end; MALAT1 has pleiotropic
abundance and localizes to the nucleus.(15)
UP-REGULATION OF LIVER
MALAT1 LEVELS STRATIFIES
PATIENTS INTO THE
HISTOLOGIC PHENOTYPES
ASSOCIATED WITH DISEASE
SEVERITY
Clinical, biochemical, and histologic features of
NAFLD patients and controls are presented in Table 1.
We found that MALAT1 is constitutively expressed in
the liver. However,MALAT1 abundance in the liver was
significantly associated with NAFLD severity (P 5 1 3
10–6). Specifically, analyses performed on the exploratory
and replication sets revealed that liver MALAT1 expres-
sion was up-regulated 1.75-fold (P 5 0.029) and 3.6-
fold (P5 0.012) in patients with NASH compared with
those diagnosed with simple steatosis (NAFL), respec-
tively (analysis of covariance adjusted by age, homeosta-
sis model assessment, and body mass index [BMI]) (Fig.
2A). Differences between MALAT1 expression levels in
control and NAFL liver samples were not statistically
significant (exploratory set, P5 0.9).
In addition, by grouping patients according to the
severity of their NAFLD histologic features, we
observed a significant association with the level of
MALAT1 expression in the liver. Specifically, greater
abundance of MALAT1 was observed in patients with
higher scores of ballooning degeneration (P 5
0.0001), lobular inflammation (P 5 0.0025), and the
presence of fibrosis (P5 13 10–7) (Fig. 2B).
Likewise,MALAT1 abundance in the liver was signif-
icantly and positively correlated with the results yielded
by biochemistry tests, including serum levels of alanine
aminotransferase (Spearman R, 0.30; P5 0.016), aspar-
tate aminotransferase (R, 0.29; P 5 0.008), and alkaline
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phosphatase (R, 0.37; P 5 0.0009) as well as with the
presence of surrogate biomarkers of hepatocellular apo-
ptosis (cytokeratin-18 [R, 0.52; P5 0.04]).
In contrast, liver MALAT1 expression was not asso-
ciated with the presence of type 2 diabetes or cardio-
vascular disease or with any metabolic parameters
examined, including peripheral insulin resistance
(homeostasis model assessment of insulin resistance),
glucose-related parameters, or lipid traits.
COMMONALITY IN DISEASE
PATHOGENIC PATHWAYS OF
CHRONIC LIVER DISEASES:
MALAT1 UP-REGULATION IS A
SHARED MOLECULAR EVENT IN
IMMUNE-MEDIATED CHRONIC
INFLAMMATORY DAMAGE
We further postulated that chronic inflammatory
liver diseases that involve both viral and sterile
autoimmune-mediated processes might share common
pathogenic/signaling pathways that are independent of
the underlying event that triggered liver injury. More-
over, we hypothesized that liver MALAT1 up-
regulation could be a common molecular mechanism
in the pathogenesis of chronic liver damage. To test
this hypothesis, we profiled liver expression levels of
MALAT1 in two independent samples of patients
comprising individuals with chronic HCV infection
and those diagnosed with autoimmune diseases. Rela-
tive to NAFL, the expression levels of liver MALAT1
were significantly higher (P 5 1 3 10–7, one-way
analysis of variance) in all patients diagnosed with the
remaining chronic liver diseases (NASH, autoim-
mune, and chronic HCV) examined in this study
(Fig. 3A). Specifically, liver MALAT1 abundance was
significantly up-regulated in NASH (3.58-fold
increase, P 5 0.0008; nonparametric Mann-Whitney
U test), autoimmune liver diseases (4.47-fold increase,
P 5 0.03), and chronic HCV (2-fold increase, P 5
0.04), as shown in Fig. 3A. Notably, the differences
between the levels of MALAT1 expression in NASH
patients and those diagnosed with autoimmune liver
diseases were not statistically significant (Fig. 3A).
Clinical features of patients with chronic HCV and
TABLE 1. CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF THE WHOLE STUDY SAMPLE
ACCORDING TO DISEASE STATUS
Exploratory Stage Replication Stage
Variable (mean 6 SD) Controls NAFL NASH NAFL NASH
Number of subjects 13 32 15 15 34
Female (%) 60 65 66 60 56
Age, years 40 6 9.6 40.6 6 10 44 6 12 49.7 6 10.5 49 6 11
BMI, kg/m2 58.5 6 14 53 6 12.4 46 6 7.5 30 6 3.5 33.4 6 7
Waist circumference, cm - - - 104.8 6 6.5 112 6 15
Waist:hip ratio - - - 1.0 6 0.03 1.0 6 0.08
Arterial hypertension (%) 20 37.5 54 45 53
Type 2 diabetes (%) 15 32 73 21 47
Fasting plasma glucose, mg/dL 102 6 20.5 104.5 6 31 134 6 71 100 6 16 123 6 51
Fasting plasma insulin, mg/dL 11.3 6 6 14 6 7 30 6 52 15 6 11 17 6 10.4
HOMA-IR index 2.7 6 1.5 3.5 6 2 17 6 48 3.6 6 2.4 5 6 4.8
Hb1C 6.5 6 1.4 6.4 6 1.4 6.8 6 2 5.9 6 0.7 7.5 6 2.7
Total cholesterol, mg/dL 180 6 25 183 6 40 177 6 46 196 6 47 209 6 42
HDL-cholesterol, mg/dL 42 6 10 47 6 9.5 40 6 8.5 54 6 13 50 6 14
LDL-cholesterol, mg/dL 115 6 22 128 6 27 127 6 38 119 6 48.5 126 6 32
Triglycerides, mg/dL 116 6 46 143 6 53 155 6 53 183 6 95 175 6 95
ALT, U/L 20.5 6 9 32.5 6 21.5 44 6 21 55 6 30.5 80 6 41
AST, U/L 20.4 6 13 24 6 14 34 6 19 37.5 6 15 54 6 26
AP, U/L 86 6 16 76 6 20 83 6 27 198 6 100 169 6 88
Degree of steatosis, % 0 6 0 32 6 25 46 6 24 44 6 32 64.5 6 21
Lobular inflammation (0-3) 0 6 0 0.3 6 0.6 1.4 6 0.9 0.4 6 0.5 1 6 0.58
Portal inflammation (0-2) 0 6 0 0.4 6 1 1.06 6 1 0.0 6 0.0 0.2 6 0.5
Hepatocellular ballooning (0-2) 0 6 0 0.15 6 0.3 1.07 6 0.7 0.0 6 0.0 1 6 0.6
Fibrosis stage (1-4) 0 6 0 0.03 6 0.17 1.7 6 1.2 0.0 6 0.0 1.6 6 1.1
NAS 0 6 0 2 6 2 4.6 6 1 2.4 6 1.5 4.6 6 1.4
Abbreviations: ALT alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; Hb1C, hemoglobin A1c;
HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; LDL, low-density lipoprotein; NAS,
NAFLD activity score.
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autoimmune liver diseases are shown in Supporting
Table S2.
MALAT1 TARGET GENE (lncRNA–
mRNA) INTERACTION: LIVER
EXPRESSION OF MALAT1
SIGNIFICANTLY CORRELATES
WITH LIVER VASCULAR
ENDOTHELIAL GROWTH
FACTOR A mRNA LEVELS
MALAT1 has proangiogenic properties that are
mediated by induction of vascular endothelial growth
factor A (VEGFA) expression. The biological interac-
tion between MALAT1 and VEGFA has been robustly
validated in in vitro experiments(16); however, whether
this association is also observed in liver tissue remains
unknown. Therefore, we measured the liver abundance
of VEGFA in all patients with NAFLD included in
the study (NAFL and NASH in the bariatric cohort as
well as patients with MetS). We observed that the lev-
els of the two RNAs (MALAT1, VEGFA) were
significantly and positively correlated (Spearman R,
0.59; P 5 5 3 10–8; Fig. 3B). Moreover, we found
that liver MALAT1 abundance was significantly and
positively associated with circulating lactic acid levels
(Spearman R, 0.50; P 5 0.01).
MECHANISTIC MODELING:
ANALYSIS OF THE MALAT1
NETWORK OF EXPRESSION
INTERACTIONS
To gain insight into the role of MALAT1 in chronic
liver damage, we performed mechanistic modeling. To
this end, we first explored the MALAT1-associated
transcriptional network using the FARNA tool. The
search was narrowed to human liver tissue by applying
appropriate filters. FARNA predicted 106 transcrip-
tion factors (TFs), including GO biological process,
pathways, and reactome (Supporting Fig. S2); details
are fully disclosed in Supporting Tables S3-S5.
Integration of predicted MALAT1-associated TFs
into pathways and biological processes is shown in
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FIG. 2. Up-regulation of liver MALAT1 levels stratifies patients into the histologic phenotypes associated with disease severity. (A)
Liver abundance of MALAT1 is significantly associated with NAFLD histologic severity. Each bar represents mean 6 SE values. In
each sample, liver abundance of MALAT1 was expressed as normalized by the liver expression levels of a housekeeping gene (RPL19
mRNA). Fold change pertains to the increase in NASH with respect to NAFL. Human expression analysis was conducted in two
stages. Discovery set (NAFLD morbidly obese, sample size n 5 47 [NAFL n 5 32, NASH n 5 15]) and control group (n 5 13);
and replication set (NAFLD-MetS, sample size n 5 49, NAFL n 5 15, NASH n 5 34). P value denotes statistical significance
ascertained with analysis of variance adjusted by age, homeostasis model assessment of insulin resistance, and BMI; #P, NASH versus
NAFL within groups; *P, NASH versus control subjects in morbidly obese category; nonparametric Mann-Whitney U test. (B) Liver
MALAT1 expression levels are significantly associated with the full spectrum of NAFLD histologic severity. The severity of histologic
features was graded according to scores described by Brunt et al.(12) and Kleiner et al.(11) as indicated in the Methods section.
Horizontal lines refer to mean value. Abbreviations: Lob infla, lobular inflammation; RPL19, ribosomal protein L19.
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FIG. 3. MALAT1 up-regulation is a common molecular event in immune response-mediated chronic inflammatory liver damage.
(A) MALAT1 expression in chronic liver diseases. MALAT1 expression in the liver of patients with NAFLD and MetS (NAFL
and NASH, n 5 49), therapy naive subjects with chronic HCV infection (n 5 44), and patients with autoimmune liver diseases
(primary biliary cholangitis and autoimmune hepatitis, n 5 21). Each bar represents mean 6 SE values. In each sample, liver
abundance of MALAT1 was expressed as normalized by the liver expression levels of a housekeeping gene (RPL19 mRNA). The
P value is the statistical significance indicated by the nonparametric Mann-Whitney U test. (B) MALAT1 liver expression signifi-
cantly correlates with VEGFA mRNA levels. Correlation between log-transformed liver MALAT1 RNA and log-transformed
VEGFA mRNA expression levels. Liver abundance of both transcripts is expressed as normalized by the liver expression levels of
a housekeeping gene (RPL19 mRNA). The P value stands for Spearman R for nontransformed variables. (C) MALAT1 gene
network pathways. Pathway was predicted by the resource PANTHER version 12.0, released on July 10, 2017, based on the list
of liver TFs predicted by the FARNA tool. Bars represent the results yielded by the overrepresentation test (P < 0.05, adjusted
by Bonferroni correction for multiple testing) after contrasting the list of predicted TFs associated with the MALAT1 gene tran-
scription network with the whole human genome transcriptome (n 5 21,002 genes); PANTHER Overrepresentation Test
(release 20170413). STAT proteins and JAK involve intracellular signal transduction. Regulation of TFs by RNA II polymerase
is the process that modulates the frequency, rate, or extent of transcription from an RNA polymerase II promoter. Primary meta-
bolic processes are the normal anabolic and catabolic processes (carbohydrate, cellular amino acid, lipid, nucleobase-containing
compound, and protein metabolic process as well as tricarboxylic acid cycle). Metabolic processes are chemical reactions and
pathways, including anabolism and catabolism, by which living organisms transform chemical substances; these processes include
macromolecular processes, such as DNA repair and replication and protein synthesis and degradation. Biosynthetic processes are
the chemical reactions and pathways resulting in the formation of substances; this is typically the energy-requiring part of metab-
olism in which simpler substances are transformed into more complex ones. Nitrogen compound metabolic processes are path-
ways involving organic or inorganic compounds that contain nitrogen. Developmental processes occur at the structural level, such
as a subcellular structure, cell, tissue, or organ, or organism, and modify the pertinent structure over time, transforming it from
an initial condition to a later condition. (D) MALAT1 expression levels in inflammatory-related cells. Data were retrieved from
the integrated data set of human gene expression patterns (BioGPS).(17) Expression was measured using the U133 Affymetrix
chip; *MALAT1 abundance is expressed as gcrma-normalized expression data relative to fluorescence intensity. Grna: Because
there are multiple probes for each transcript on the microarray, the intensity values were summarized using various data process-
ing algorithms. (E) MALAT1 blockade by antisense oligonucleotides: analysis of gene expression network. The heat map illus-
trates gene expression levels (mRNAs) of transcription factors predicted by the FARNA tool in a mechanistic experiment that
involved MALAT1 blockade by antisense nucleotides. Values represent log-transformed up/down fold changes of differentially
expressed mRNAs in cells (human diploid fibroblasts) transfected with MALAT1 antisense oligonucleotides relative to the level
of untreated cells. Data retrieved from the Gene Expression Omnibus, accession number GDS5352. Abbreviations: Adj. P Val,
Bonferroni correction for multiple testing of nominal P values; CD, cluster of differentiation; chr-HCV, chronic HCV; gcrma,
analysis package used for microarray data in R/Bioconductor; logFC, log-transformed up/down fold change; NS, not significant;
RPL19, ribosomal protein L19.
                                                                                                                                      
HEPATOLOGY COMMUNICATIONS, Vol. 2, No. 6, 2018 SOOKOIAN ET AL.
661
Fig. 3C. Test analysis showed that both the Janus
kinase-signal transducers and activators of transcrip-
tion (JAK-STAT) cascade (Pe 5 1.15 3 10
–2) and the
response to interferon-c (Pe 51.79 3 10
–4) were sta-
tistically overrepresented (Pe denotes an empirical P
value after applying Bonferroni correction for multiple
testing).
Given that the infiltration of liver tissue by inflam-
matory cells is regarded as a hallmark feature of chronic
liver damage, we aimed to ascertain whether MALAT1
is expressed in the cellular milieu that is commonly
involved in mediating the immune response. Hence,
we retrieved gene expression data pertaining to
MALAT1 abundance in inflammatory response-related
cells from the integrated data set of human gene
expression patterns (BioGPS).(17) The analysis indi-
cated that MALAT1 is highly expressed in a large
number of immune-related cells, including lymphocyte
and leukocyte subsets, although the relative abundance
seems to be different in B and T cells, with higher lev-
els of expression noted in the latter (Fig. 3D).
Finally, to determine the functional relevance of the
MALAT1 gene expression network, we examined dif-
ferential mRNA levels of predicted TFs in cells trans-
fected with MALAT1 antisense oligonucleotides
(blockade of gene expression) relative to the level
observed in untreated cells. To this end, we used the
Gene Expression Omnibus (GEO) to retrieve raw
data sets (accession number GDS5352) in which nor-
mal human diploid fibroblasts (WI38) were depleted
of MALAT1.(18) Transcriptome analysis at the
genome-wide level was assessed by Illumina Human
HT-12 V4.0 expression beadchip. We specifically
focused on the level of predicted TFs, and our analyses
were performed using the FARNA tool, as described
above.
After Bonferroni correction for multiple testing, we
found that MALAT1 depletion was significantly asso-
ciated with 16 of the 106 predicted TFs, the levels of
which were either down- or up-regulated (Fig. 3E).
Among TFs significantly associated with MALAT1
knockdown expression, we found nuclear receptors
that are critically involved in NAFLD pathogenesis
(peroxisome proliferator activated receptor a [PPARa]
and nuclear receptor subfamily 1 group F member 1
[RORa]); master transcriptional regulators (MAF
BZIP transcription factor [MAF]) that control the T
helper type 2 differentiation pathway; transcription
factor Dp-1 (TFDP1), which controls the cell cycle
and is involved in cell proliferation and apoptosis;
SIN3 transcription regulator family member A
(SIN3A) involved in transcriptional repression of circa-
dian target genes; cyclic adenosine monophosphate
response element-binding protein 1 (CREB1), which
modulates mitochondrial function; and high mobility
group AT-Hook 1 (HMGA1), a TF involved in meta-
static progression of cancer cells.
Interestingly, VEGFA was shown to be differentially
down-regulated after MALAT1 depletion (0.44-fold
decrease, nominal P 5 0.0019, adjusted P 5 0.02;
GEO data set accession number GSE43830)(18)
(http://bio-annotation.cn/lncrna2target/).
Discussion
In this work, we explored the role of lncRNAs in
the severity of NAFLD. We integrated knowledge
derived from high-throughput technologies that was
obtained by employing multiscale systems biology
modeling methods that included literature mining,
analysis of NAFLD-interaction network at the gene/
protein level, and prediction and prioritization of
lncRNA2mRNA interactions from different cellular
and tissue types. This strategy resulted in the selection
of MALAT1 as a candidate lncRNA with a potentially
relevant function in liver tissue. We next translated
this knowledge into the clinical setting and examined a
large collection (n 5 174) of unique liver tissue speci-
mens linked to clinical, biochemical, and histologic
records of patients. We found that, relative to their
expression in the control tissue and samples obtained
from patients diagnosed with simple steatosis
(NAFL), the levels of MALAT1 were significantly
higher in the NASH subsamples. Liver MALAT1
abundance was significantly associated with the full
spectrum of histologic severity, including ballooning
degeneration, lobular inflammation, and fibrosis. Of
note, these associations were unrelated to any meta-
bolic parameter, such as insulin resistance or lipid
traits, or any underlying associated comorbidity.
We further hypothesized that deregulated MALAT1
expression could be a common perturbed molecular
feature of chronic liver diseases, regardless of whether
the diseases are triggered by infectious or sterile
inflammatory causes. To this end, we extended the
quantification of MALAT1 abundance to the liver of
untreated chronic HCV patients and patients diag-
nosed with autoimmune liver diseases. Interestingly,
we observed that MALAT1 up-regulation occurred not
only in NASH cases but also in immune-mediated
chronic liver diseases.
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Mechanistic exploration that involved quantification
of VEGFA mRNA levels (a validated target of
MALAT1) as well as analysis of the MALAT1 gene
regulatory network retrieved from the transcript data
stored in the GEO database, yielded clinically relevant
results. For example, interactome assessment uncov-
ered significant biological pathways, including JAK-
STAT and response to interferon-c, for which pertur-
bation or dysfunction could be linked to chronic liver
injury of any cause rather than a particular disease phe-
notype. Furthermore, gene co-expression network
analysis of MALAT1 blockade by antisense oligonu-
cleotides revealed a significant role of this lncRNA in
metabolic processes as well as in immune-response
modulation, circadian rhythm control, and lipid
metabolism. In line with our results, a recent report
demonstrated that MALAT1 may promote hepatic
steatosis by increasing sterol regulatory element bind-
ing transcription factor 1 stability through the inhibi-
tion of its ubiquitination.(19)
Why is the lncRNA MALAT1 relevant to the
progression of NAFLD? The first and perhaps the
most obvious reason for its relevance is its ability to
modify an aggressive phenotype. In our investigation,
MALAT1 abundance discriminated patients with dif-
ferent NAFLD histologic outcomes. Specifically, while
our data do not suggest that MALAT1 expression
levels are able to discriminate patients into different
fibrosis scores, they are robust in differentiating simple
steatosis versus NASH. Of note, MALAT1 up-
regulation was independent of the underlying meta-
bolic status, which suggests that this lncRNA plays a
significant role in triggering and perpetuating the
human NASH phenotype rather than merely mediat-
ing the accumulation of lipids in the liver. This line of
reasoning is in agreement with work that involved
both transcriptome analysis and epigenetic profiling of
the liver tissue in NAFLD. Authors of those studies,
including us, demonstrated that the transition from
normal liver to fatty liver is associated with perturbed
metabolic pathways involving master genes that control
glucose and lipid metabolism.(4,5,20) Conversely, the
progression into a more severe phenotype redirects the
transcriptome toward pathways biologically related
with mitochondrial dysfunction(21,22) and malig-
nancy.(4,5,10) In this respect, MALAT1 represents a
remarkable functional and versatile molecule that mod-
ulates a myriad of signaling pathways, including cell
cycle control,(18) immune balance,(23) and endothelial
cell function and vessel growth.(24) These phenomena,
when present concurrently, escalate in complexity to
entail cell proliferation and migration,(25) apoptosis,
fibrosis,(26) and malignancy.(27)
The exact mechanism(s) by which liver MALAT1
expression is regulated are still unknown; however, criti-
cal pathways, including modification of the chromatin
state, as well as modulation of proteosome machinery
are promising candidates. Functional experiments
involving knockdown of MALAT1 expression by anti-
sense oligonucleotides in human multiple myeloma cell
lines resulted in alterations of proteasome subunit of
nuclear respiratory factor 1 and 2 (NRF1, NRF2) genes
as well as in endoplasmic reticulum stress. In turn,
NRF1 seems to promote MALAT1 expression, provid-
ing a positive feedback loop.(28) Together, the evidence
suggests that liver MALAT1 expression could be regu-
lated by epigenetic mechanisms.
Second, exploration of liver VEGFA mRNA, a well-
known driver of tumor angiogenesis, showed that
levels of the two RNAs (MALAT1, VEGFA) are sig-
nificantly and positively correlated. Likewise, liver
MALAT1 abundance correlated with serum lactate
concentration. These findings support the notion that
the progression of NAFL to NASH involves not only
inflammation and fibrogenesis but also metabolic
reprogramming into a cancer-related transcriptional
signature. Alternatively, angiogenesis may be regarded
as a wound healing response and thus being part of the
normal response of the liver to injury or hypoxia.
Third, in terms of NASH phenotypic plasticity, the
pattern of liverMALAT1 expression seems to segregate
the disease spectrum into the two well-known clusters
of NAFLD histologic lesions, one of which is observed
in individuals who are nonmorbidly obese while the
other is noted in those who are morbidly obese.(29-31)
Specifically, while we found that MALAT1 levels were
significantly higher in liver tissue samples taken from
NASH patients compared to controls or those in the
NAFL group, the magnitude of the effect was signifi-
cantly higher in patients with NAFLD and MetS than
in patients with NAFLD and individuals who were
morbidly obese (P 5 0.0001). While we could not find
any biological explanation for this result, we observed
that liver MALAT1 expression was significantly and
negatively correlated with the BMI of all patients
included in the study; this was obvious because the dif-
ference between the BMI values of the two groups of
patients was highly significant (BMI in patients who
were morbidly obese was 50.92 6 11.48 kg/m2 com-
pared to 32.48 6 6.01 kg/m2 measured for patients
with MetS; P < 0.0001). Further studies will be
required to elucidate whether the observed differences in
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the pattern of MALAT1 expression can explain the dis-
tinctive histologic picture of NAFLD observed in
patients who are morbidly obese.(29-31) It could be argued,
however, that RNA expression levels in liver specimens
isolated by surgical procedures behave differently from
liver tissue obtained by percutaneous liver biopsy.(32)
This is a robust reason that supports the importance of a
replication stage that was included in the present study.
Fourth, in terms of gene network-associated path-
ways, MALAT1 involvement overlaps common mecha-
nisms of liver injury. More explicitly, we found that
MALAT1 overexpression was a common molecular fea-
ture in chronic liver diseases, including NASH and
autoimmune diseases. This observation could provide a
novel framework for understanding the pathogenesis of
chronic liver damage, which suggests that convergent
pathophenotypes (inflammation and fibrosis) share sim-
ilar molecular mediators. Therefore, the natural history
of chronic liver damage, regardless of the leading cause,
ultimately results in cirrhosis and/or eventually HCC.
Last, owing to the complexity of liver tissue, particu-
larly during NASH development in which an intricate
cellular milieu coexists, we cannot rule out the possibility
that MALAT1 abundance is derived from multicellular
sources. In fact, we showed that MALAT1 expression is
particularly abundant in cells of the immune system.
Together, whether originating from hepatocytes or tissue-
resident macrophages, neutrophils, natural killer cells, or
lymphocytes that colonized the liver from the circulating
compartment, all of the above-mentioned observations
support the notion that MALAT1 participates in a posi-
tive feedback loop of inflammation !tissue damage $
tissue repair! fibrogenesis! cancer.
A potential limitation of our study stems from its
observational cross-sectional nature, which prevented
us from proving causality. We have initiated the longi-
tudinal assessment of paired liver biopsies taken at least
5 years apart from patients with NAFLD who had
progressed to an advanced disease stage. Remarkably,
measurements of liver MALAT1 abundance showed a
dramatic 8-fold increase in a patient who progressed
from NAFL to NASH fibrosis and a 29-fold increase
in a NASH patient who progressed from fibrosis 0 to
fibrosis 3. This observation is particularly significant as
fibrosis stage is known to be associated with long-term
outcomes in patients with NAFLD.(33,34) Certainly, a
more comprehensive study is needed but will require
time and an adequate sample size.
Our findings may have clinical and therapeutic
implications. First, the notion that MALAT1 is
involved in the regulation of JAK-STAT signaling
suggests an interesting clue for the mechanism by
which NAFL progresses into NASH and eventually to
cirrhosis and/or HCC.(35) Min and coworkers(36)
observed that the STAT3 pathway is activated in
patients with NAFLD. In addition, we have reported
an association between STAT3 polymorphisms in the
susceptibility to NAFLD and disease severity.(37)
Finally, the fact that deregulated expression of liver
MALAT1 was seen at convergent pathophenotypes,
which include inflammation, fibrosis, and immune-
response related mechanisms, supports the use of sys-
tems biology to predict novel therapeutic agents that
target pathophenotypes rather than specific diseases.
An interesting example of this strategy is the use of a
farnesoid X receptor (FXR, formally NR1H4) agonist
(obeticolic acid) for the treatment of both primary bili-
ary cholangitis(38) and NASH.(39)
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